- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Zyvox use shows increased mortality
Results of a clinical trial comparing linezolid (Zyvox, Pfizer) with vancomycin, oxacillin, or dicloxacillin show that patients treated with linezolid had a higher mortality rate compared with patients treated with other antibiotics.
Results of a clinical trial comparing linezolid (Zyvox, Pfizer) with vancomycin, oxacillin, or dicloxacillin show that patients treated with linezolid had a higher mortality rate compared with patients treated with other antibiotics. The chance of death was higher in patients infected with gram-negative organisms or a mix of gram-negative and gram-positive organisms, or in those patients who had no infection when they entered the study. Patients were being treated for intravascular catheter-related bloodstream infections, including catheter-site infections. Patients treated for gram-positive infections showed no increase in mortality. The FDA reminds practitioners that linezolid is not approved for the treatment of gram-negative catheter-related infections.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
